Linike Medical Group Ltd (LNMG) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Linike Medical Group Ltd $0.01, price $0.01, upside +80.8%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Linike Medical Group Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $0.0028 – $4.73 · fair‑value band $0.0089 – $0.0095 · the $0.0051 price screens below the $0.0092 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Linike Medical Group in your weekly email
Every Wednesday you see whether Linike Medical Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Linike Medical Group Ltd. engages in the renewable energy business. The company is involved in the creation of a solar farm in India. It also focuses on commercial real estate development business. The company was formerly known as Litian Group Inc. and changed its name to Linike Medical Group Ltd. in August 2021. Linike Medical Group Ltd.
Show more
Linike Medical Group Ltd. engages in the renewable energy business. The company is involved in the creation of a solar farm in India. It also focuses on commercial real estate development business. The company was formerly known as Litian Group Inc. and changed its name to Linike Medical Group Ltd. in August 2021. Linike Medical Group Ltd. is based in Calgary, Canada.
Stock analysis
Linike Medical Group Ltd (LNMG) currently trades at $0.0051, while our model-based Fair Value estimate is $0.0092, implying the stock looks roughly 44.7% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $0.0600 per share, and 6 of the 6 models we run sit above the $0.0051 price.
Bear case: the Earnings-Based group reads lowest at $0.0400, and 0 of the 6 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0089 (bear) to $0.0095 (bull), the price of $0.0051 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Linike Medical Group Ltd reported revenue of $10.7M in FY2025 versus $69.3K in FY2012, a compound +47.3%/yr. Reported net income was $3.1M in FY2025.
Key figures
Market cap $6.7M · Net margin 28.9% · Return on assets (EBIT) −1,092% · Free cash flow −$263K · Net debt $16.9M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 87% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 81%, LNMG screens cheaper than that median.
Fair Value models
Bear $0.0089Fair Value $0.0092Bull $0.0095
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−18.2%
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.3%
’12
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+46.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+46.0%
Dividend (yield on the price)0.0%
Profit margin 2012 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−127% → 29%
Compare Linike Medical Group Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside+80.8% · Top 25%
Profitability
Return on assets−172.4% · Bottom 25%
Net margin (TTM)28.9% · Top 25%
Operating margin (TTM)0.0% · Below median
Growth and dividend
Revenue growth0.0% · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Linike Medical Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/LNMG
Frequently asked questions
Is Linike Medical Group Ltd (LNMG) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0092 versus a price of $0.0051, about +81% upside (undervalued).
What is the fair value of LNMG?
Our model-based fair value for Linike Medical Group Ltd is $0.0092 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.0051.
What is the quality score of LNMG?
Linike Medical Group Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Linike Medical Group Ltd (LNMG)?
Our model-based price target is the fair value of $0.0092 (as of Sep 27, 2026) from 6 valuation models. Cautious scenario $0.0089, optimistic scenario $0.0095. It is a calculation from audited fundamentals, not an analyst target.
What is the Linike Medical Group Ltd stock forecast for 2026?
Our models put fair value at $0.0092, about +81% upside versus a price of $0.0051 (undervalued). Cautious scenario $0.0089, optimistic scenario $0.0095. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Linike Medical Group Ltd (LNMG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Linike Medical Group Ltd it is $0.0092 per share (as of Sep 27, 2026), against a price of $0.0051. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Linike Medical Group Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, LNMG trades below its calculated fair value: price $0.0051, fair value $0.0092, a gap of about +81% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LNMG?
No. The price is what the market pays today ($0.0051); the fair value is what the company's own numbers justify ($0.0092). For Linike Medical Group Ltd the two are $0.0041 per share apart. That gap is exactly why we show both numbers side by side.
How much is Linike Medical Group Ltd worth?
The market values Linike Medical Group Ltd at about $6.7M (market capitalisation, as of Sep 27, 2026). Per share that is $0.0051; our models calculate a fair value of $0.0092 per share.
What do the bullish and bearish scenarios say about LNMG?
Our models span a range for Linike Medical Group Ltd: cautious scenario $0.0089, base $0.0092, optimistic $0.0095 per share (as of Sep 27, 2026, price $0.0051). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is LNMG from its 52-week high?
Linike Medical Group Ltd trades at $0.0051, about 87% below its 52-week high of $0.0390 and 2% above the low of $0.0050 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0092 is for.
Which stocks are comparable to Linike Medical Group Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Linike Medical Group Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0051, calculated fair value $0.0092 (+81%), Quality Score 47/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LNMG calculated?
We run Linike Medical Group Ltd through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0092, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Linike Medical Group Ltd currently trades 45 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Linike Medical Group Ltd (LNMG)?
The closing price on Oct 1, 2026 was $0.0051. Our model-based fair value is $0.0092, about +81% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Linike Medical Group Ltd right now?
The price is below even our cautious bear case ($0.0089). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (47/100) at a price below fair value, the discount is the argument here, not the business quality. The models converge in a tight band ($0.0089 to $0.0095), unusually little disagreement for a valuation.
Key figures of Linike Medical Group Ltd
How large is the market capitalisation of Linike Medical Group Ltd (LNMG)?
The market capitalisation of Linike Medical Group Ltd is $6.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the net margin of Linike Medical Group Ltd (LNMG)?
The net margin of Linike Medical Group Ltd is 28.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Linike Medical Group Ltd (LNMG)?
On an EBIT basis the return on assets of Linike Medical Group Ltd is −1,092% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Linike Medical Group Ltd (LNMG) generate?
The free cash flow of Linike Medical Group Ltd is −$263K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Linike Medical Group Ltd (LNMG) carry?
The net debt of Linike Medical Group Ltd is $16.9M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Linike Medical Group Ltd in the live analysis
One click puts Linike Medical Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026